Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H18N2O |
Molecular Weight | 230.3055 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2
InChI
InChIKey=PXWLVJLKJGVOKE-UHFFFAOYSA-N
InChI=1S/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25221653Curator's Comment: description was created based on several sources, including
https://www.medchemexpress.com/Propyphenazone.html?gclid=CKPT7oP5jM8CFUKeGwodv10NsQ
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25221653
Curator's Comment: description was created based on several sources, including
https://www.medchemexpress.com/Propyphenazone.html?gclid=CKPT7oP5jM8CFUKeGwodv10NsQ
Propyphenazone is a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity. The coupling of propyphenazone with other widely used acidic NSAIDs such as ketoprofen, ibuprofen, and diclofenac produced mutual prodrugs with synergistic analgesic effects. It was introduced for the treatment of different types of pain and fever and rheumatic disorders. Propyphenazone structurally relates to aminophenazone it has been associated with severe blood dyscrasias.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/15334450
Curator's Comment: Hoffmann-La Roche had substituted an isopropyl group for the amino group of 4-amino-diethyl antipyrine. The resulting drug was propyphenazone http://www.druglead.com/cds/propyphenazone.html # 1934 to Hoffmann-La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25221653 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | saridon Approved UseIt is indicated for: headache, toothache, nerve pain , lumbago, muscular pain, menstrual pain and fever and pain with influenza and viral rhinitis; fever and pain after vaccination Launch Date1983 |
|||
Primary | saridon Approved UseIt is indicated for: headache, toothache, nerve pain , lumbago, muscular pain, menstrual pain and fever and pain with influenza and viral rhinitis; fever and pain after vaccination Launch Date1983 |
|||
Primary | saridon Approved UseIt is indicated for: headache, toothache, nerve pain , lumbago, muscular pain, menstrual pain and fever and pain with influenza and viral rhinitis; fever and pain after vaccination Launch Date1983 |
|||
Primary | saridon Approved UseIt is indicated for: headache, toothache, nerve pain , lumbago, muscular pain, menstrual pain and fever and pain with influenza and viral rhinitis; fever and pain after vaccination Launch Date1983 |
|||
Primary | saridon Approved UseIt is indicated for: headache, toothache, nerve pain , lumbago, muscular pain, menstrual pain and fever and pain with influenza and viral rhinitis; fever and pain after vaccination Launch Date1983 |
PubMed
Title | Date | PubMed |
---|---|---|
Derivative ratio spectra-zero crossing spectrophotometry and LC method applied to the quantitative determination of paracetamol, propyphenazone and caffeine in ternary mixtures. | 2001 Dec |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Drug-induced hepatitis with hepatic granuloma due to saridon. | 2002 |
|
The onset of action and the analgesic efficacy of Saridon (a propyphenazone/paracetamol/ caffeine combination) in comparison with paracetamol, ibuprofen, aspirin and placebo (pooled statistical analysis). | 2002 |
|
Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea. | 2002 Aug 5 |
|
Advanced fibre optical scanning in thin-layer chromatography for drug identification. | 2002 May 25 |
|
[Current aspects of the treatment of migraine]. | 2003 Jul-Aug |
|
Wavelet analysis for the multicomponent determination in a binary mixture of caffeine and propyphenazone in tablets. | 2004 Apr |
|
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. | 2004 Oct |
|
Detection and identification of phenazone-type drugs and their microbial metabolites in ground and drinking water applying solid-phase extraction and gas chromatography with mass spectrometric detection. | 2004 Oct 1 |
|
Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. | 2005 |
|
[Abuse pattern of analgesics in chronic daily headache: a study in the general population]. | 2005 Dec |
|
Dipyrone and aminopyrine are effective scavengers of reactive nitrogen species. | 2006 |
|
Mobility of pharmaceuticals carbamazepine, diclofenac, ibuprofen, and propyphenazone in miscible-displacement experiments. | 2006 Feb 1 |
|
Inhibition of human neutrophil oxidative burst by pyrazolone derivatives. | 2006 Feb 15 |
|
Celosomy is associated with prenatal exposure to cyclooxygenase inhibitors. | 2006 Mar |
|
Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. | 2006 Mar |
|
Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. | 2006 Oct |
|
Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. | 2007 Feb |
|
Development of a multicommuted flow-through optosensor for the determination of a ternary pharmaceutical mixture. | 2007 Jan 17 |
|
Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. | 2007 Jan-Feb |
|
Development and validation of chemometrics-assisted spectrophotometry and liquid chromatography methods for the simultaneous determination of the active ingredients in two multicomponent mixtures containing chlorpheniramine maleate and phenylpropanolamine hydrochloride. | 2007 Jul-Aug |
|
Simultaneous determination of paracetamol, caffeine and propyphenazone in ternary mixtures by micellar electrokinetic capillary chromatography. | 2007 Mar 1 |
|
Investigation of the behavior and metabolism of pharmaceutical residues during purification of contaminated ground water used for drinking water supply. | 2007 Nov |
|
Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007 Nov |
|
Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
Treatment of a landfill leachate containing compounds of pharmaceutical origin. | 2008 |
|
Rejection of pharmaceuticals in nanofiltration and reverse osmosis membrane drinking water treatment. | 2008 Aug |
|
Determination of caffeine and associated compounds in food, beverages, natural products, pharmaceuticals, and cosmetics by micellar electrokinetic capillary chromatography. | 2008 Feb |
|
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. | 2008 Jul |
|
Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage. | 2008 Sep 1 |
|
Synaptopodin regulates plasticity of dendritic spines in hippocampal neurons. | 2009 Jan 28 |
|
Quantification of 4-methylaminoantipyrine, the active metabolite of dipyrone, in human plasma. | 2009 May |
|
Acute myocardial infarction and Kounis syndrome. | 2009 May 15 |
|
The characteristics of enriched nitrifier culture in the degradation of selected pharmaceutically active compounds. | 2009 Nov 15 |
|
A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic. | 2009 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3492378
single oral doses of 150 and 300 mg
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02BB74
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
WHO-ATC |
N02BB74
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
WHO-VATC |
QN02BB04
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
WHO-VATC |
QN02BB54
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
WHO-ATC |
N02BB04
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
||
|
WHO-ATC |
N02BB54
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092130
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
207-539-2
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
m9252
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
2309
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
SUB10125MIG
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
OED8FV75PY
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
2848
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
34710
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
C72124
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
Propyphenazone
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL28318
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
479-92-5
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
3778
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
C009077
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
DTXSID6023529
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
135538
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
OED8FV75PY
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY | |||
|
DB13524
Created by
admin on Fri Dec 15 15:19:50 GMT 2023 , Edited by admin on Fri Dec 15 15:19:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY